H-HMTEVVRHC-OH
Ref. 3D-PP47216
| 1mg | 217.00 € | ||
| 10mg | 253.00 € | ||
| 100mg | 455.00 € |
Product Information
Peptide H-HMTEVVRHC-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-HMTEVVRHC-OH include the following: Adoptive cell therapy targeting neoantigens: a frontier for cancer research Z Wang, YJ Cao - Frontiers in immunology, 2020 - frontiersin.orghttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.00176 SABRE: Self-Attention Based model for predicting T-cell Receptor Epitope Specificity Z Wang, Y Shen - bioRxiv, 2023 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2023.10.02.560555.abstract Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia W Zhou, J Yu, Y Li, K Wang - Experimental Hematology & Oncology, 2022 - Springerhttps://link.springer.com/article/10.1186/s40164-022-00353-3 Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity RA Mariuzza , D Wu, BG Pierce - Frontiers in Immunology, 2023 - frontiersin.orghttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1303304 TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia R Rahme, T Braun, JJ Manfredi, P Fenaux - Biomedicines, 2023 - mdpi.comhttps://www.mdpi.com/2227-9059/11/4/1152 Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers P Malekzadeh, A Pasetto, PF Robbins - The Journal of , 2021 - Am Soc Clin Investighttps://www.jci.org/articles/view/123791 T cell recognition of tumor neoantigens and insights into T cell immunotherapy MJW Sim , PD Sun - Frontiers in Immunology, 2022 - frontiersin.orghttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.833017 627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine K Cooke, J Estrada, J Zhan, J Werner, F Lee, A Shetty - 2020 - jitc.bmj.comhttps://jitc.bmj.com/content/8/Suppl_3/A376.2.abstract Epitope identification for p53R273C mutant J Zhang, M Liu, Y Chen, Z Zhou - Immunity , 2023 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/iid3.752 Systematic discovery of Neoepitope-HLA pairs for neoantigens shared among patients and tumor types HR Gurung , AJ Heidersbach, M Darwish - Nature , 2023 - nature.comhttps://www.nature.com/articles/s41587-023-01945-y Discovery of prevalent, clinically actionable tumor neoepitopes via integrated biochemical and cell-based platforms H Gurung , A Heidersbach, M Darwish, P Chan , J Li - bioRxiv, 2022 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2022.10.27.513529.abstract Targeting a neoantigen derived from a common TP53 mutation EHC Hsiue , KM Wright, J Douglass , MS Hwang - Science, 2021 - science.orghttps://www.science.org/doi/abs/10.1126/science.abc8697 629 Targeting a shared TP53 neoantigen with bispecific T cell retargeting antibody E Hsiue , K Wright, J Douglass , M Hwang, B Mog - 2020 - jitc.bmj.comhttps://jitc.bmj.com/content/8/Suppl_3/A377.2.abstract Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen D Wu, DT Gallagher, R Gowthaman , BG Pierce - Nature , 2020 - nature.comhttps://www.nature.com/articles/s41467-020-16755-y 628 IL-2 augments immTAC-dependent T cell activation and tumour cell killing D Gascoyne, K Petrovic, K Ranade, D Depoil - 2020 - jitc.bmj.comhttps://jitc.bmj.com/content/8/Suppl_3/A377.1.abstract
Chemical properties
Technical inquiry about: 3D-PP47216 H-HMTEVVRHC-OH
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
